Photosensitive lichenoid skin reaction to capecitabine.
Photosensitive lichenoid skin reaction to capecitabine.
复制标题
DOI：
10.1186/s12885-017-3882-4
复制
发表时间：
2017-12-19
期刊：
影响因子：
3.8
通讯作者：
Burkard ME
中科院分区：
文献类型：
--
作者：
Shah RA;Bennett DD;Burkard ME
卡培他滨是氟尿嘧啶的一种口服前药，氟尿嘧啶是治疗许多实体瘤恶性肿瘤的常用药物。皮肤病反应是常见的各种化疗药物，但并不常见的卡培他滨的使用报告。当发生皮疹的不良反应时，通常会去除引起不适的药剂。我们在这里报告一个不寻常的情况下，光敏苔藓样皮疹由于卡培他滨，这是保守的管理没有重大改变的治疗。诊断为接受卡培他滨治疗的IV期乳腺癌的73岁女性在夏季出现皮疹，经活检证实为苔藓样光敏性皮疹，可能的致病药物为卡培他滨。尽管对治疗有反应，但她的治疗最初被暂停，在皮肤科评估后开始局部类固醇治疗。考虑到她对治疗的反应，重新开始用药，并指导使用防晒霜和防晒霜，并完成局部类固醇疗程，直至皮疹消退。药物相关皮疹往往导致恶性肿瘤治疗中断或改变，尽管反应。鉴于卡培他滨广泛用于许多不同的实体瘤，重要的是要认识到这种光敏相关的皮疹，并开始适当的预防措施，阳光安全和局部类固醇，以允许最小限度地中断治疗，并继续使用卡培他滨。
Capecitabine is an oral prodrug of fluorouracil, which is a common agent used in the management of many solid tumor malignancies. Dermatologic reaction is common with various chemotherapy agents but is not commonly reported in the use of capecitabine. When adverse reactions of rashes occur, the offending agent is typically removed. We report here an unusual case of photosensitive lichenoid rash due to capecitabine which is managed conservatively without major alteration in treatment. Seventy-three year old female with a diagnosis of stage IV breast cancer undergoing management with capecitabine presents with a rash during the summer months that is biopsy proven to be lichenoid photosensitive rash with likely offending agent being capecitabine. Her treatment was initially held despite having response to treatment, started on topical steroids after evaluation by dermatology. Given her response to treatment, drug was resumed with instructions to use sun precaution, sunscreen, and to complete course of topical steroids until rash resolution. Drug-related rashes tend to lead to disruptions or alterations in treatments of malignancies, despite responses. Given the wide use of capecitabine in many different solid tumors, it is important to recognize this photosensitive related skin rash and to initiate appropriate precautions of sun safety and topical steroids to allow minimal disruptions in therapy and continue use of capecitabine.
影响因子：
51.1
作者：
Bachelot, Thomas;Romieu, Gilles;Labbe-Devilliers, Catherine
通讯作者：
Labbe-Devilliers, Catherine
影响因子：
2.1
作者：
Al-Shamsi, Humaid O.;Kee, Bryan K.;Wolff, Robert A.
通讯作者：
Wolff, Robert A.
影响因子：
45.3
作者：
Bartsch, Rupert;Wenzel, Catharina;Steger, Guenther G.
通讯作者：
Steger, Guenther G.